Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer
2025-10-01
|
| Colección: | Discover Oncology |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1007/s12672-025-03569-x |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|